Clinical trials: Stomatitis
Cancer, Lymphoma
Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)
To evaluate whether palifermin (rHuKGF) administered as a single dose is non-inferior to 3 consecutive doses of palifermin in reducing the incidence of severe oral mucositis (World Health Organization [WHO] grade 3 and 4).
- Conditions
- Cancer, Lymphoma, Leukemia
- Trial name
- NCT00109031
- Testing
- palifermin, Total Body Irradiation, Cyclophosphamide
- Volunteers
- 47 people
- Sponsor
- Swedish Orphan Biovitrum
Oral Mucositis
Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
The purpose of this study is to assess the safety and tolerability of AG013 (genetically modified L. lactis bacteria engineered to secrete human Trefoil Factor 1), and to explore the ability of AG013 to attenuate the course and…
- Trial name
- NCT00938080
- Testing
- AG013
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- ActoGeniX N.V.
Oral Mucositis, Head and Neck Cancer
EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer
Randomized, double-blind, placebo-controlled study for the treatment of head and neck cancer(HNC), to assess the ability of EN3285 to prevent or delay the onset of severe oral mucositis(OM).
- Trial name
- NCT00574860
- Testing
- EN3285, Standard of care
- Where
- 2 sites in United States
- Volunteers
- 240 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Stomatitis
The Clinical Study for Evaluation of Efficacy and Safety of EGF on Oral Mucositis in Radiation Therapy Patients
The purpose of this Study is to evaluate the efficacy and safety of rhEGF on oral mucositis in patients receiving the radiation therapy or the concurrent chemo-radiotherapy
- Trial name
- NCT01099891
- Testing
- rhEGF
- Where
- 2 sites in South Korea
- Volunteers
- 300 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Oral Mucositis
Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day
The purpose of the study is to evaluate the efficacy, safety and tolerability of topically administered AG013 compared to placebo for reducing Oral Mucositis (OM) in patients undergoing chemoradiation for the treatment of head…
- Trial name
- NCT03234465
- Testing
- AG013
- Where
- 50 sites in United States, Belgium and 2 more
- Volunteers
- 200 people
- Sponsor
- Oragenics, Inc.
Head & Neck Cancer, Oral Mucositis
A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.
Most patients who receive radiation therapy for head and neck cancer develop painful sores in the mouth called oral mucositis. For many of them, these sores are severe and result in debilitating pain.
- Trial name
- BEAM-Pain (NCT07672236)
- Testing
- BupiZenge 25 mg, Lidocaine viscous 2%
- Where
- 11 sites in Denmark, Germany and 2 more
- Volunteers
- 150 people
- Sponsor
- OncoZenge AB
Radiation-induced Oral Mucositis
Effects of CKI for Oral Mucositis Caused by Radiotherapy for Head and Neck Cancer
Oral mucositis (OM) is an acute side effect of radiotherapy for head and neck cancer (HNC). OM associated pain affects oral functions and nutrition of the patient that may result in discontinuity of treatment.The purpose of this…
- Trial name
- NCT04204382
- Testing
- Levofloxacin Injection, Compound Kushen Injection（CKI）
- Where
- 12 sites in China
- Volunteers
- 144 people
- Sponsor
- Shanxi Zhendong Pharmacy Co., Ltd
Head and Neck Cancer
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer
The purpose of this study is to evaluate the efficacy and safety of palifermin (recombinant human keratinocyte growth factor, rHuKGF) in reducing the incidence of severe oral mucositis in subjects with locally advanced head and…
- Trial name
- NCT00131638
- Testing
- Palifermin
- Volunteers
- 241 people
- Sponsor
- Amgen
Oral Mucositis, Nausea
ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial
RATIONALE: Polymerized (cross-linked) sucralfate malate paste (ProThelial) may be an effective single therapy approach for the management of chemoradiation mucositis, treating and preventing its occurrence in the oral cavity…
- Conditions
- Oral Mucositis, Nausea, Vomiting, Diarrhea
- Trial name
- NCT02016807
- Testing
- ProThelial
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Ashley Downs Bioscience
Oral Mucositis Due to Radiation, Radiation Dermatitis
Feasibility and Safety of CareMin650 in Patients at Risk of or Suffering From Oral Mucositis and/or Radiation Dermatitis
The main objective of the present study is to investigate the feasibility, safety and tolerability of CareMin650 in patients with 1) head \& neck cancer at high risk of or suffering from oral mucositis and/or radiation dermatitis…
- Trial name
- SafePBM (NCT03988556)
- Testing
- Photobiomodulation using CareMin650 at 6 Joules (curative intent), Photobiomodulation using CareMin650 at 3 Joules (prophylactic intent)
- Where
- 5 sites in France
- Volunteers
- 72 people
- Sponsor
- NeoMedLight
Squamous Cell Carcinoma of the Oral Cavity and Oropharynx, Oral Mucositis
DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer
To assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis in patients receiving chemoradiation treatment for the treatment of head and neck cancer
- Trial name
- NCT03237325
- Testing
- SGX942
- Where
- 53 sites in United States, Belgium and 3 more
- Volunteers
- 266 people
- Sponsor
- Soligenix
Oral Mucositis, Stem Cell Transplant Complications
Study of a New Medical Device for Oral Mucositis
This is a single-center randomized controlled trial of a new medical device (Bocaliner™) that has been designed to improve the treatment of chemotherapy-induced oral mucositis in patients undergoing cancer treatment.
- Trial name
- MDOM (NCT05104268)
- Testing
- Bocaliner
- Where
- Armenia
- Sponsor
- E2Bio Life Sciences, LLC
Stomatitis, Radiation Effects
Safety & Efficacy Study of Benzydamine Oral Rinse for the Treatment of Oral Mucositis (Mouth Sores) Resulting From Radiation Therapy for Cancer of the Oral Cavity, Oropharynx, or Nasopharynx
The purpose of this study is to compare the effectiveness and safety of benzydamine hydrochloride 0.15% oral rinse to a vehicle oral rinse in the treatment of radiation-induced oral mucositis, and to compare the care normally…
- Trial name
- NCT00051441
- Testing
- Benzydamine Hydrochloride 0.15% Oral Rinse
- Volunteers
- 605 people
- Sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Oral Mucositis, Lymphoma
Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT
Evaluate the efficacy and safety for the prevention of oral mucositis and PK of MIT-001 for lymphoma or multiple myeloma patients receiving conditioning chemotherapy for autologous hematopoietic stem cell…
- Conditions
- Oral Mucositis, Lymphoma, Multiple Myeloma, Hematologic Cancer
- Trial name
- Capella (NCT05493800)
- Testing
- MIT-001, normal saline
- Where
- 2 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- MitoImmune Therapeutics
Ebola Virus Disease
Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults
The purpose of this study is to assess the safety profile of the Zaire Ebola vaccine and the strength of the immune response.
- Trial name
- NCT02718469
- Testing
- Ebola Vaccine - low dose, Ebola Vaccine - mid dose, Ebola Vaccine - high dose
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Auro Vaccines LLC
Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.
Patients diagnosed with Stevens-Johnson syndrome and Toxic Epidermal Necrolysis were confirmed based on the investigators national diagnostic criteria.
- Trial name
- NCT01696500
- Testing
- Intravenous immunoglobulin
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Oral Mucositis
Gelclair at Conditioning or After Oral Mucositis Diagnosed vs. Magic Mouth Wash in Stem Cell Transplant Recipients
Patients receiving high-dose chemotherapy/conditioning prior to stem cell transplantation (SCT) are at high risk for developing painful lesions in the oral cavity, known as oral mucositis (OM).
- Trial name
- NCT03490396
- Testing
- Gelclair, First® Mouthwash BLM
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Midatech Pharma US Inc.
Head and Neck Cancer, Oral Mucositis (Ulcerative) Due to Radiation
Efficacy and Safety of CareMin650 for Prevention of Oral Mucositis in HNC Patients Starting Radiotherapy
Oral mucositis (OM) can affect up to 90% of head and neck cancer (HNC) patients treated with radiation therapy (RT). The Mucositis Study Group of the Multinational Association of Supportive Care in Cancer and International…
- Conditions
- Head and Neck Cancer, Oral Mucositis (Ulcerative) Due to Radiation, Radiation Therapy Complication
- Trial name
- PrOMiSE (NCT04699487)
- Testing
- Photobiomodulation
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- NeoMedLight
Oral Mucositis
The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients
The purpose of this study is to explore the protective effect and safety of soluble beta-1,3/1,6-glucan compared to placebo in oral mucositis in head and neck patients receiving radiotherapy or chemoradiotherapy.
- Trial name
- NCT00289003
- Testing
- Soluble beta-1,3/1,6-glucan
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Biotec Pharmacon ASA
Graft Versus Host Disease, Hematologic Malignancies
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
The main purpose of this study is to evaluate the effect of palifermin versus placebo in the reduction of severe acute graft versus host disease (GVHD) and severe oral mucositis.
- Trial name
- NCT00189488
- Testing
- Palifermin, Conditioning Regimen, Allogeneic stem cell transplant
- Volunteers
- 155 people
- Sponsor
- Swedish Orphan Biovitrum